West Pharmaceutical Stock Surges 7%, Adding $1.9 Billion, As Company Lifts 2026 Outlook
The injectable-drug packaging supplier raised its 2026 sales and earnings targets, but guided fourth-quarter growth well below the third quarter.
West Pharmaceutical, which makes containment and delivery systems for injectable drugs, saw its shares climb 6.66% to $430.54 in Thursday trading, as of 11:47 a.m. ET, a new 52-week high that added about $1.9 billion in market value. The move followed a third-quarter report that raised the company's 2026 forecast for sales and adjusted earnings.
A raised outlook on wider margins
Third-quarter revenue was $874.5 million, up 8.7% from a year earlier, with adjusted earnings of $2.66 a share, the company reported. Investors responded to stronger margins on premium vial stoppers.
West now expects 2026 revenue of $3.41 billion to $3.42 billion and adjusted earnings of $9.38 to $9.48 per share. It also said it bought back $231 million of its stock in the quarter.
The shares were on pace for a fourth straight daily gain and their biggest one-day rise since April 23. West's market value stood at $30.3 billion Thursday.
A beat with a cooling fourth quarter
Management said on the earnings call that the margin gains are not "the New Floor," and guided fourth-quarter growth well below the third quarter's pace.
High-value components, led by GLP-1-related products, made up 53% of revenue, the company said.
Up 47% this year
West sells stoppers, seals, syringe and cartridge components, vials and self-injection devices to biologic, generic, pharmaceutical, diagnostic and medical device companies. Its revenue comes from two segments: Proprietary Products, sold mainly to drug companies, and Contract-Manufactured Products, which designs and assembles complex devices.
The stock was up about 47% year to date as of Wednesday's close, well ahead of the S&P 500's roughly 13% gain.
Thursday's rally leaves the stock at a 52-week high, set against management's own warning that fourth-quarter growth will be well below the third quarter's.
Sources
- West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates — Yahoo Finance
- West Pharmaceutical beats top-line and bottom-line estimates; raises FY26 outlook | Seeking Alpha — seekingalpha.com
- Compared to Estimates, West Pharmaceutical (WST) Q3 Earnings: A Look at Key Metrics — Yahoo Finance
- West Pharmaceutical Servs Q3 2026 Earnings Call Transcript — benzinga.com
- West (WST) Stock Could Be 28% Overvalued As Cash Flow Falls Short — Yahoo Finance
- The company's filing (West Pharmaceutical) — SEC filing
- West Pharmaceutical — Form 10-Q for the quarter ended 2026-06-30 (quarterly results) — SEC EDGAR
More on West Pharmaceutical
- West Pharmaceutical Says GLP-1 Surge Had 'Nothing One-Offish' — But Margins Are Not 'The New Floor'
- West Pharmaceutical's New CEO Says The Bar For Acquisitions Is 'Incredibly High' As Customers Cut Supplier Lists
- West Pharmaceutical Raises 2026 Profit Outlook To $9.38-$9.48 A Share As High-Value Components Jump 19.7%